Ignite Creation Date:
2024-05-05 @ 9:42 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00007592
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2000-12-29
Brief Title:
Hypertension Screening and Treatment Program
Sponsor:
US Department of Veterans Affairs
Organization:
VA Office of Research and Development
Study Overview
Official Title:
VA HYPERTENSION SCREENING AND TREATMENT PROGRAM PILOT STUDY
Status:
COMPLETED
Status Verified Date:
2003-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypertension is one of the most common medical problems in the United States and in the VA health care system It has been well-documented that hypertension can be effectively treated However there remain important unresolved clinical questions in the area of antihypertensive treatment For example how much is mortality affected by visit compliance blood pressure control and type of antihypertensive agent Or are some regimens associated with more morbidity than others Or are there inexpensive regimens that are as effective as more expensive regimens The amount of data that is available from this demonstration project currently 6100 patients will help address these questions The answers to these questions should result in better care for veterans with hypertension
Detailed Description:
Primary Hypothesis A variety of clinical questions of major importance can be addressed using clinical data routinely obtained in the VA Hypertension Screening and Treatment Program For example treatment of mild hypertension reduces the risk of strokes and heart attacks
Secondary Hypothesis Target organ damage occurs despite blood pressure control
Intervention Chlorthalidone furosemide hydrochlorothiazide metolazone indapamide amiloride spironolactone triamterene atenolol metoprolol nadolol pindolol propranolol timolol acebutolol penbutolol clonidine guanethidine methydopa prazosin guanadrel labetalol reserpine guanfacine hydralazine minoxidil captopril enalapril lisinopril diltiazem nifedipine verapamil nicardipine dyazide maxzide pargyline terazosin other anti-hypertensives
Primary Outcomes Blood Pressure and Target Organ Damage
Study Abstract Hypertension is one of the most common medical problems in the United States and in the VA health care system It has been well-documented that hypertension can be effectively treated However there remain important unresolved clinical questions in the area of antihypertensive treatment For example how much is mortality affected by visit compliance blood pressure control and type of antihypertensive agent Or are some regimens associated with more morbidity than others Or are there inexpensive regimens that are as effective as more expensive regimens The amount of data that is available from this demonstration project currently 6100 patients will help address these questions The answers to these questions should result in better care for veterans with hypertension
This demonstration project provides for central collection of a standard set of clinical data for patients at some of the Hypertension Screening and Treatment Program clinics thereby setting up a national data base on the treatment of hypertension The primary objective of this project is to demonstrate the value of establishing this type of database The database is being used to estimate the average annual cost of different antihypertensive regimens to determine the cost-efficacy of different therapies and the least expensive effective therapy and to address some major unanswered clinical questions that require large populations and long-term patient care data There are currently 13 medical centers participating
Secondary Hypothesis Target organ damage occurs despite blood pressure control
Intervention Chlorthalidone furosemide hydrochlorothiazide metolazone indapamide amiloride spironolactone triamterene atenolol metoprolol nadolol pindolol propranolol timolol acebutolol penbutolol clonidine guanethidine methydopa prazosin guanadrel labetalol reserpine guanfacine hydralazine minoxidil captopril enalapril lisinopril diltiazem nifedipine verapamil nicardipine dyazide maxzide pargyline terazosin other anti-hypertensives
Primary Outcomes Blood Pressure and Target Organ Damage
Study Abstract Hypertension is one of the most common medical problems in the United States and in the VA health care system It has been well-documented that hypertension can be effectively treated However there remain important unresolved clinical questions in the area of antihypertensive treatment For example how much is mortality affected by visit compliance blood pressure control and type of antihypertensive agent Or are some regimens associated with more morbidity than others Or are there inexpensive regimens that are as effective as more expensive regimens The amount of data that is available from this demonstration project currently 6100 patients will help address these questions The answers to these questions should result in better care for veterans with hypertension
This demonstration project provides for central collection of a standard set of clinical data for patients at some of the Hypertension Screening and Treatment Program clinics thereby setting up a national data base on the treatment of hypertension The primary objective of this project is to demonstrate the value of establishing this type of database The database is being used to estimate the average annual cost of different antihypertensive regimens to determine the cost-efficacy of different therapies and the least expensive effective therapy and to address some major unanswered clinical questions that require large populations and long-term patient care data There are currently 13 medical centers participating
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None